Manufacturers of many types of patient-monitoring devices can add or improve remote-monitoring features without first getting regulatory clearance during the COVID-19 public health crisis, the US Food and Drug Administration said in an immediately-in-effect guidance document issued on 20 March.
The move is intended to help reduce the burden the novel coronavirus places on the health care system, the guidance...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?